On the public citation graph

Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK

https://doi.org/10.1002/cam4.413
0 signed · 127 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ijc.10435openalex-snapshot
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
inferredcites →https://doi.org/10.1007/s00109-007-0159-4openalex-snapshot
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
inferredcites →https://doi.org/10.1016/j.bbrc.2007.04.137openalex-snapshot
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer
inferredcites →https://doi.org/10.1016/j.bbrc.2012.05.120openalex-snapshot
A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK
inferredcites →https://doi.org/10.1016/j.canlet.2014.05.020openalex-snapshot
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
inferredcites →https://doi.org/10.1016/j.cell.2010.06.011openalex-snapshot
Cell Signaling by Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/j.prp.2011.07.001openalex-snapshot
ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript
inferredcites →https://doi.org/10.1016/s0002-9440(10)65042-0openalex-snapshot
Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma
inferredcites →https://doi.org/10.1016/s0092-8674(03)00190-9openalex-snapshot
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
inferredcites →https://doi.org/10.1021/ci400188qopenalex-snapshot
Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
inferredcites →https://doi.org/10.1038/modpathol.2010.213openalex-snapshot
Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
inferredcites →https://doi.org/10.1038/nature05945openalex-snapshot
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/nm.2673openalex-snapshot
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
inferredcites →https://doi.org/10.1038/sj.onc.1200849openalex-snapshot
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
inferredcites →https://doi.org/10.1053/j.gastro.2004.02.021openalex-snapshot
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
inferredcites →https://doi.org/10.1056/nejmc1013224openalex-snapshot
Crizotinib in Anaplastic Large-Cell Lymphoma
inferredcites →https://doi.org/10.1056/nejmoa044238openalex-snapshot
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
inferredcites →https://doi.org/10.1056/nejmoa1007478openalex-snapshot
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
inferredcites →https://doi.org/10.1056/nejmoa1215530openalex-snapshot
Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
inferredcites →https://doi.org/10.1093/jnci/djt378openalex-snapshot
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
inferredcites →https://doi.org/10.1097/jto.0000000000000094openalex-snapshot
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
inferredcites →https://doi.org/10.1126/science.1062538openalex-snapshot
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
inferredcites →https://doi.org/10.1126/science.8122112openalex-snapshot
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1126/scitranslmed.3003316openalex-snapshot
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
inferredcites →https://doi.org/10.1158/0008-5472.can-10-4041openalex-snapshot
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
inferredcites →https://doi.org/10.1158/0008-5472.can-11-1340openalex-snapshot
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2393openalex-snapshot
Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2906openalex-snapshot
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-3260openalex-snapshot
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
inferredcites →https://doi.org/10.1158/1541-7786.mcr-08-0522openalex-snapshot
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
inferredcites →https://doi.org/10.1158/1541-7786.mcr-14-0157openalex-snapshot
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma
inferredcites →https://doi.org/10.1158/2159-8290.cd-13-0846openalex-snapshot
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1182/blood.v89.5.1483openalex-snapshot
A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation
inferredcites →https://doi.org/10.1200/jco.2008.19.8853openalex-snapshot
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
inferredcites →https://doi.org/10.1200/jco.2011.37.8588openalex-snapshot
Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications
inferredcites →https://doi.org/10.1200/jco.2013.31.15_suppl.8031openalex-snapshot
First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
inferredcites →https://doi.org/10.1371/journal.pmed.0020073openalex-snapshot
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
inferredcites →https://doi.org/10.1517/13543784.2012.690031openalex-snapshot
Inhibitors of the anaplastic lymphoma kinase
inferredcites →https://doi.org/10.17758/ur.u0616224openalex-snapshot
Identification of Squamous Cell Carcinoma Associated Proteins by Proteomics and Loss of Beta Tropomyosin Expression in Esophageal Cancer
inferredcites →https://doi.org/10.2147/ott.s38868openalex-snapshot
Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
inferredcites →https://doi.org/10.3748/wjg.v12.i44.7104openalex-snapshot
Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4656812openalex-extracted
inferred← citeshttps://doi.org/10.1002/cmdc.202100166openalex-snapshot
Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
inferred← citeshttps://doi.org/10.1002/med.21409openalex-snapshot
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
inferred← citeshttps://doi.org/10.1007/s00018-015-2117-6openalex-snapshot
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
inferred← citeshttps://doi.org/10.1007/s00894-026-06727-2openalex-snapshot
A structure-based virtual screening approach to identify novel anaplastic lymphoma kinase inhibitors
inferred← citeshttps://doi.org/10.1007/s10637-019-00802-7openalex-snapshot
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma
inferred← citeshttps://doi.org/10.1007/s11523-016-0460-7openalex-snapshot
Ceritinib: a Review in ALK-Positive Advanced NSCLC
inferred← citeshttps://doi.org/10.1007/s11864-017-0513-xopenalex-snapshot
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS
inferred← citeshttps://doi.org/10.1016/b978-0-12-809400-6.00016-0openalex-snapshot
Crizotinib
inferred← citeshttps://doi.org/10.1016/b978-0-12-821774-0.00005-xopenalex-snapshot
Resistance mechanisms to ALK TKIs in tumors other than lung cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2019.113666openalex-snapshot
Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells
inferred← citeshttps://doi.org/10.1016/j.bioorg.2023.106653openalex-snapshot
Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.108950openalex-snapshot
A review: recent developments of co-targeted TRK (tropomyosin receptor kinases) inhibitors for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.109706openalex-snapshot
Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance
inferred← citeshttps://doi.org/10.1016/j.bmc.2015.12.004openalex-snapshot
Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmc.2020.115715openalex-snapshot
Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.02.009openalex-snapshot
Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer
inferred← citeshttps://doi.org/10.1016/j.cellsig.2022.110264openalex-snapshot
EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling
inferred← citeshttps://doi.org/10.1016/j.cllc.2016.03.005openalex-snapshot
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review
inferred← citeshttps://doi.org/10.1016/j.cllc.2021.06.011openalex-snapshot
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
inferred← citeshttps://doi.org/10.1016/j.ctrv.2022.102430openalex-snapshot
Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2023.102561openalex-snapshot
Proteolysis targeting chimeras in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2019.03.005openalex-snapshot
Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.12.026openalex-snapshot
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.11.008openalex-snapshot
Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R
inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.12.060openalex-snapshot
Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation
inferred← citeshttps://doi.org/10.1016/j.ejmech.2018.04.019openalex-snapshot
Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs
inferred← citeshttps://doi.org/10.1016/j.ejmech.2018.09.012openalex-snapshot
Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118053openalex-snapshot
The past, present, and future of ALK-targeted drug discovery
inferred← citeshttps://doi.org/10.1016/j.jbc.2024.107994openalex-snapshot
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations
inferred← citeshttps://doi.org/10.1016/j.jtho.2016.03.018openalex-snapshot
Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib
inferred← citeshttps://doi.org/10.1016/j.lungcan.2017.02.003openalex-snapshot
Optimal management of ALK -positive NSCLC progressing on crizotinib
inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.04.002openalex-snapshot
HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model
inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.01.001openalex-snapshot
Appearance of an ALK mutation conferring resistance to crizotinib in non–small cell lung cancer harboring oncogenic ROS1 fusion
inferred← citeshttps://doi.org/10.1016/j.neo.2025.101133openalex-snapshot
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
inferred← citeshttps://doi.org/10.1016/j.phrs.2017.01.007openalex-snapshot
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
inferred← citeshttps://doi.org/10.1016/j.rechem.2022.100752openalex-snapshot
Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors
inferred← citeshttps://doi.org/10.1016/j.rmr.2019.02.008openalex-snapshot
Stratégies thérapeutiques dans le cancer bronchique non à petites cellules ALK positif de stade IV
inferred← citeshttps://doi.org/10.1016/j.semcancer.2016.11.002openalex-snapshot
New strategies for targeting drug combinations to overcome mutation-driven drug resistance
inferred← citeshttps://doi.org/10.1016/j.trecan.2016.05.010openalex-snapshot
Resisting Resistance: Targeted Therapies in Lung Cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5b01136openalex-snapshot
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6b00064openalex-snapshot
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6b00487openalex-snapshot
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.7b01039openalex-snapshot
Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design
inferred← citeshttps://doi.org/10.1038/s41388-022-02453-0openalex-snapshot
ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3
inferred← citeshttps://doi.org/10.1038/s41598-018-28752-9openalex-snapshot
Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations
inferred← citeshttps://doi.org/10.1080/13543784.2017.1324572openalex-snapshot
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer
inferred← citeshttps://doi.org/10.1080/14728214.2018.1527902openalex-snapshot
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
inferred← citeshttps://doi.org/10.1080/14737140.2024.2344648openalex-snapshot
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
inferred← citeshttps://doi.org/10.1080/14756366.2023.2227779openalex-snapshot
Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R
inferred← citeshttps://doi.org/10.1093/annonc/mdw305openalex-snapshot
Crizotinib resistance: implications for therapeutic strategies
inferred← citeshttps://doi.org/10.1093/neuonc/now197openalex-snapshot
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
inferred← citeshttps://doi.org/10.1111/cas.13721openalex-snapshot
Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND ‐9
inferred← citeshttps://doi.org/10.1155/2019/9028309openalex-snapshot
Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-16-0569openalex-snapshot
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-16-1415openalex-snapshot
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non–Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-15-1056openalex-snapshot
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
inferred← citeshttps://doi.org/10.1177/1753465815597834openalex-snapshot
The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
inferred← citeshttps://doi.org/10.1186/s12911-018-0680-0openalex-snapshot
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics
inferred← citeshttps://doi.org/10.1186/s13045-019-0768-8openalex-snapshot
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
inferred← citeshttps://doi.org/10.1186/s13046-025-03535-zopenalex-snapshot
Mechanistic models position ceritinib as a nuclear integrity disrupting therapy in pediatric liver tumors
inferred← citeshttps://doi.org/10.1200/po.21.00184openalex-snapshot
STRN-ALKFusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
inferred← citeshttps://doi.org/10.1371/journal.pone.0308747openalex-snapshot
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer
inferred← citeshttps://doi.org/10.1515/med-2025-1289openalex-snapshot
OKAIN: A comprehensive oncology knowledge base for the interpretation of clinically actionable alterations
inferred← citeshttps://doi.org/10.18632/oncotarget.17033openalex-snapshot
A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma
inferred← citeshttps://doi.org/10.18632/oncotarget.26428openalex-snapshot
Targeted therapies for advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.27875openalex-snapshot
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
inferred← citeshttps://doi.org/10.18632/oncotarget.3122openalex-snapshot
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
inferred← citeshttps://doi.org/10.18632/oncotarget.8173openalex-snapshot
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
inferred← citeshttps://doi.org/10.18632/oncotarget.8508openalex-snapshot
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells,Drosophilaand mice
inferred← citeshttps://doi.org/10.21037/tlcr.2016.06.10openalex-snapshot
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
inferred← citeshttps://doi.org/10.21037/tlcr.2019.09.15openalex-snapshot
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
inferred← citeshttps://doi.org/10.21037/tlcr.2020.02.07openalex-snapshot
Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
inferred← citeshttps://doi.org/10.21203/rs.3.rs-6614711/v1openalex-snapshot
Variantscape: Using Large Language Models to Build a Comprehensive Landscape of Cancer Variants for Precision Oncology
inferred← citeshttps://doi.org/10.22159/ijap.2022v14i4.44388openalex-snapshot
FORMULATION AND OPTIMIZATION OF CERITINIB LOADED NANOBUBBLES BY BOX-BEHNKEN DESIGN
inferred← citeshttps://doi.org/10.2217/fon-2017-0262openalex-snapshot
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
inferred← citeshttps://doi.org/10.24265/horizmed.2024.v24n2.07openalex-snapshot
Propuesta de estrategias terapéuticas combinadas para KRAS en cáncer de pulmón de células no pequeñas a partir de análisis in silico
inferred← citeshttps://doi.org/10.3389/fonc.2022.1019624openalex-snapshot
Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib
inferred← citeshttps://doi.org/10.3390/cancers10030062openalex-snapshot
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
inferred← citeshttps://doi.org/10.3390/cancers13236003openalex-snapshot
Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
inferred← citeshttps://doi.org/10.3390/curroncol29100618openalex-snapshot
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3390/ijms252011214openalex-snapshot
Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3390/ijms27062587openalex-snapshot
Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals
inferred← citeshttps://doi.org/10.3390/jcm8070998openalex-snapshot
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
inferred← citeshttps://doi.org/10.4137/bic.s29326openalex-snapshot
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
inferred← citeshttps://doi.org/10.5306/wjco.v6.i5.104openalex-snapshot
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.